Treatment for the autoimmune disease MS has been tested in three phase I clinical trials, one completed, where two different subsets, Dex-tolDCs loaded with myelin peptides or aquaporin-4-derived peptides (AQP4) and VitD3-tolDCs loaded with several myelin peptides, were tested. The gene discussed is AQP4; the disease is myeloid sarcoma.